ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Vontobel Financial Products GmbH

Vontobel Financial Products GmbH (F38640)

0.00
0.00
( 0.00% )

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

F38640 News

Official News Only
0 articles were found

Discussion

View Full Feed
PegnVA PegnVA 6 minutes ago
Anything for attention.
jondoeuk jondoeuk 6 minutes ago
I've heard that an MD Anderson team is developing an off-the-shelf IL-21 armoured CAR-NK cell therapy that will target EGFR and IL13Ra2 https://www.cell.com/cancer-cell/abstract/S1535-6108(24)00272-1

They are also testing another off-the-shelf NK cell therapy with containing deleted o
GILD
fuagf fuagf 9 minutes ago
dbergh, First many immunodeficient people wear masks to protect their lives, that first interviewer is as ignorant as you.

The 2nd again exhibits the ignorance of the one you see as smart:

Type of hormone therapy may determine whether trans men continue to menstruate
Bull_Dolphin Bull_Dolphin 15 minutes ago
Matt Gaetz on involvement with Israel in Iran:

https://worldnews.whatfinger.com/2025/06/17/daaammmn-matt-gaetz-trump-and-iran-israel-hot-take-%f0%9f%94%a5%f0%9f%94%a5/
jttcomm jttcomm 19 minutes ago
Oh boy. You are the wit. So who is this toxic lender you speak of. No offense but it is difficult to believe the stories that go around and around.
NBRI
joeycav11 joeycav11 26 minutes ago
The amount of detail in this new program is extraordinary. You can sense the exuberance of the author.
The main takeaway is that dcvax will be the poster child of this new hugely exciting program.
There isn’t any other exciting drug on the horizon that could get people excited.That’s
NWBO
joeycav11 joeycav11 26 minutes ago
The amount of detail in this new program is extraordinary. You can sense the exuberance of the author.
The main takeaway is that dcvax will be the poster child of this new hugely exciting program.
There isn’t any other exciting drug on the horizon that could get people excited.That’s
NWBO
OzzieTrader OzzieTrader 27 minutes ago
45 million shares traded price 9.2c down 7%
DTREF
JohnKnowsIt JohnKnowsIt 43 minutes ago
Robert Hipple once wrote my opinion letter
WPFH
JohnKnowsIt JohnKnowsIt 44 minutes ago
Pretty incredible Indian river is still on the filings
WPFH
JohnKnowsIt JohnKnowsIt 45 minutes ago
Henry where are my shares? Time for some legal….
WPFH
JohnKnowsIt JohnKnowsIt 46 minutes ago
But no stocks go up in this space… it’s all about selling shares
WPFH
Pickme2 Pickme2 47 minutes ago
Keep adding...at this rate, there will be billions available and you'll be rich..
ATMH
JohnKnowsIt JohnKnowsIt 47 minutes ago
Rich but not a billionaire
WPFH
mdb1 mdb1 50 minutes ago
Futures are UP. I was 100% sure they would be way down tomorrow. What? Who knew.
MP
Pickme2 Pickme2 53 minutes ago
Just be patient...you've waited 5 years ...when there was tens of Millions... Now there's hundreds of millions!! Your time will come
ATMH
PickStocks PickStocks 56 minutes ago
No one...
COOP
PickStocks PickStocks 57 minutes ago
You may claim 41.6.....but who enforces it.....no one...you could be waiting decades thinking JPM owes you something....you may have received it from the GSA.....but the GSA was between WMI, JPM and the FDIC and JPM came away with 600+ million.....escrows were not part of it.....would like for you t
JPM
Jballer134 Jballer134 59 minutes ago
BETTER OFF DONATING THE 100$ TO A SOUP KITCHEN
CLNV
jondoeuk jondoeuk 1 hour ago
It will be interesting to see GILD's KITE-753 clinical data. The only difference between it (and KITE-363) is a reduced production time.

However, based on preclinical data, KITE-753 exhibited higher expression of both CARs and increased proportion of CCR7+/CD45RA+ T-cells* compared to
LYEL
jondoeuk jondoeuk 1 hour ago
It will be interesting to see GILD's KITE-753 clinical data. The only difference between it (and KITE-363) is a reduced production time.

However, based on preclinical data, KITE-753 exhibited higher expression of both CARs and increased proportion of CCR7+/CD45RA+ T-cells* compared to
GILD
HyGro HyGro 1 hour ago
Ah, ha, ha. Then why didn't NWBO file with the FDA??? There's no material money in a UK approval. Only the U.S. delivers serious revenue and profitable pricing. If FDA considered the P3 trial legitimate, they would have encouraged NWBO to file, but.........nothing. Even if MHRA buys it, FD
NWBO
cojoboy cojoboy 1 hour ago
You've been talking about this same shot for a year
RDAR
stervc stervc 1 hour ago
PROPHET-of-PROFITS , here are more detailed answers...

Keep in mind, this is just how I see things and why I think it is a "no brainer" to take the risk here with PSWW.

Yes, those properties were in BMXI's books in 2021-2022, but since that was an SEC filing, and per S
BMXI PSWW
Investor082 Investor082 1 hour ago
He gets his pathological lying skills from his buddy LG! Expect share price to slide whenever he posts. Works like a magic.

Can't get L application submitted in the US and reimbursement evidence support filed in UK and we are now approaching 5 years from data lock, but let's deflect
NWBO

Your Recent History

Delayed Upgrade Clock